Pharma / CMC Task Force
Mission: Accelerate the adoption of in silico technologies in pharmaceutical development, Chemistry, Manufacturing and Controls (CMC), and regulatory decision-making throughout the product lifecycle.
In silico technologies offer significant opportunities to transform pharmaceutical development and manufacturing by improving efficiency, supporting product quality and safety, reducing development costs, and accelerating the delivery of new medicines to patients.
Across the pharmaceutical product lifecycle, computational approaches can support formulation development, process understanding, technology transfer, batch size definition, and the identification and management of Critical Quality Attributes (CQAs). They can also strengthen regulatory strategies by providing scientific evidence to support decision-making and by helping address the evolving needs of pharmaceutical regulators and other healthcare stakeholders.
However, broader adoption of in silico approaches requires greater confidence in their reliability, clearer regulatory pathways, and stronger collaboration between industry, academia, and competent authorities. As pharmaceutical regulatory frameworks and strategies continue to evolve, it is essential to ensure that digital and computational technologies are recognised as valuable tools for innovation and evidence generation.
The Pharma / CMC Task Force brings together expertise from academia and industry to advance the understanding, acceptance, and practical implementation of in silico technologies in pharmaceutical development and manufacturing. It acts as a centre of expertise, supporting dialogue with regulatory authorities and healthcare stakeholders, identifying opportunities for implementation, and promoting approaches that can facilitate the integration of computational methods into pharmaceutical practice and regulatory submissions.
Goals
- Build a multidisciplinary expert community among Avicenna Alliance members, bringing together expertise in pharmaceutical sciences, CMC, computational modelling, industry, and regulatory affairs.
- Identify and promote relevant in silico applications across pharmaceutical development, manufacturing, and the broader product lifecycle, including formulation development, technology transfer, process understanding, and product quality assessment.
- Support regulatory acceptance of in silico approaches in pharmaceuticals by addressing regulatory requirements, identifying gaps, and developing recommendations for their use in evidence generation and regulatory submissions.
- Provide guidance on CMC applications, including the generation and use of in silico data to support discussions with regulatory authorities on batch size, Critical Quality Attributes (CQAs), and related development strategies.
- Engage with regulatory authorities and healthcare stakeholders to inform evolving pharmaceutical strategies and promote the integration of digital and computational technologies into regulatory activities.
- Build confidence in industry and other stakeholders by sharing knowledge, identifying good practices, and promoting scientifically sound approaches to the application of in silico technologies.
- Identify opportunities for targeted applications of in silico medicine in specific therapeutic indications and patient populations, supporting pharmaceutical innovation and the development of new medicines.